YH 4808

Drug Profile

YH 4808

Alternative Names: YH-4808

Latest Information Update: 08 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yuhan
  • Class Antiulcers; Gastric antisecretories; Small molecules
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastro-oesophageal reflux; Reflux oesophagitis
  • Discontinued NSAID-induced ulcer

Most Recent Events

  • 08 Sep 2015 YH 4808 is still in phase II trials for Gastro-oesophageal reflux in South Korea
  • 08 Sep 2015 Discontinued - Phase-II for NSAID-induced ulcer in South Korea (PO)
  • 08 Sep 2015 No recent reports on development identified - Phase-I for Gastro-oesophageal reflux (In volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top